The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index; 24 of the 24 sources its claims cite were checked for support.
What is CRISPR/Cas9?
Open accessAbstract
Clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 is a gene-editing technology causing a major upheaval in biomedical research. It makes it possible to correct errors in the genome and turn on or off genes in cells and organisms quickly, cheaply and with relative ease. It has a number of laboratory applications including rapid generation of cellular and animal models, functional genomic screens and live imaging of the cellular genome.1 It has already been demonstrated that it can be used to repair defective DNA in mice curing them of genetic disorders,2 and it has been reported that human embryos can be similarly modified.3 Other potential clinical applications include gene therapy, treating infectious diseases such as HIV and engineering autologous patient material to treat cancer and other diseases. In this review we will give an overview of CRISPR/Cas9 with an emphasis on how it may impact on the specialty of paediatrics. Although it is likely to have a significant effect on paediatrics through its impact in the laboratory, here we will concentrate on its potential clinical applications. We will also describe some of the difficulties and ethical controversies associated with this novel technology. CRISPR/Cas9 is a gene-editing technology which involves two essential components: a guide RNA to match a desired target gene, and Cas9 (CRISPR-associated protein 9)—an endonuclease which causes a double-stranded DNA break, allowing modifications to the genome (see figure 1). Figure 1 The CRISPR/Cas9 system.1 Clustered regularly interspaced palindromic repeats (CRISPR) refers to sequences in the bacterial genome. They afford protection against invading viruses, when combined with a series of CRISPR-associated (Cas) proteins. Cas9, one of the associated proteins, is an endonuclease that cuts both strands of DNA. Cas9 is directed to its target by a section of RNA. This can be synthesised as a single strand called …
Overview
CoChat Summary
TL;DR
CRISPR/Cas9 is a gene-editing technology pairing a guide RNA with the Cas9 endonuclease to create targeted double-stranded DNA breaks, enabling genome correction or gene regulation. This narrative review outlines its potential paediatric clinical applications—correcting monogenic disorders, treating HIV, and engineering somatic cells ex vivo—while flagging delivery, off-target, and germline-ethics challenges.
Key findings
- CRISPR/Cas9 requires two components: a guide RNA matching the target gene and Cas9, an endonuclease that causes a double-stranded DNA break; repair via homology-directed repair allows edits "as precise as a single base-pair," while non-homologous end joining typically yields random insertions/deletions.
- Preclinical disease applications cited: correction of the most common CF mutation in intestinal organoids from two patients restored CFTR function; AAV-delivered CRISPR/Cas9 recovered dystrophin expression and partial muscle function in a DMD mouse model; BCL11A enhancer disruption induced fetal haemoglobin in mice and primary human erythroblast cells.
- HIV: CRISPR/Cas9 targeting of the HIV-1 genome inactivated viral gene expression and replication in latently infectable cells without toxic effects, and cells could be immunised against HIV-1 infection.
- Ex vivo engineering: CRISPR/Cas9 enabled knockout and knock-in editing in primary human CD4+ T-cells (including blocking PD-1 expression), and correction of the β-thalassaemia mutation in human induced pluripotent stem cells.
Methods
- Design: narrative review article (not primary research), aimed at describing CRISPR/Cas9 and its potential impact on paediatrics, with emphasis on clinical applications and associated difficulties and ethical controversies.
- Data: no original dataset; the review synthesises published preclinical and in vitro studies (e.g., Schwank et al on CF organoids, Tabebordbar et al on DMD mice, Canver et al on BCL11A, Hu et al on HIV-1, Schumann et al on T-cells, Xie et al on β-thalassaemia iPSCs).
- Analysis: descriptive synthesis of cited literature; no formal quantitative analysis reported.
Limitations
- Stated: delivery to the right cells in vivo remains a particular issue—AAV may be too small to transduce the Cas9 gene efficiently, and a smaller Cas9 has efficacy implications; other non-viral delivery systems need optimisation.
- Stated: off-target effects elsewhere in the genome could cause long-term complications including malignancy; Cas9 concentration and expression duration matter, and long-term safety is unestablished.
- Stated: germline/embryo editing is permanent with unclear long-term consequences, and ethical boundaries remain undetermined; the review notes its therapeutic examples are predominantly directed at somatic cells. Evident from the text: the clinical applications discussed are largely preclinical or in vitro, so bedside translation is not yet demonstrated.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
23 Valid · 0 Not valid · 0 Not checked · 9 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“it has been reported that human embryos can be similarly modified.3”
§ What is CRISPR/Cas9? > INTRODUCTION
What the sources say
- Supportedcites [3] source
The Introduction reports that CRISPR/Cas9 cleaved an endogenous gene in human tripronuclear zygotes and describes mosaicism and mutations in the edited embryos. This supports the claim that human embryos can be modified, with the qualification that the study used tripronuclear rather than normal embryos. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Using adult intestinal stem cells obtained from two patients with CF, they successfully corrected the most common mutation causing CF in intestinal organoids.”
§ What is CRISPR/Cas9? > Correction of genetic disorders
What the sources say
- Supportedcites [4] source
The indexed paper describes F508 del as the most common CFTR mutation and says both patients carried it. Its concluding passage states that the authors used CRISPR/Cas9 to correct the mutation in adult intestinal stem cells from two CF patients and demonstrated function in organoids (indexed section: Abstract; page not given). (LLM, conf=0.94)
plainstates a causen = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“They demonstrated that once the mutation had been corrected, the function of the CF transmembrane conductor receptor (CFTR) was restored.4”
§ What is CRISPR/Cas9? > Correction of genetic disorders
What the sources say
- Supportedcites [4] source
The Summary states that the CFTR locus was corrected in intestinal stem cells from CF patients and that the corrected allele was fully functional in expanded organoids. The results passage reports swelling in corrected organoids, absent in untransfected controls, and concludes that the corrected allele rescued the CFTR phenotype. (LLM, conf=0.95)
boostedstates a causen = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This produces a truncated, but still functional protein.”
§ What is CRISPR/Cas9? > Correction of genetic disorders
What the sources say
- Supportedcites [5] source
The Abstract states that exon removal can produce a truncated but still functional protein. It reports that exon 23 deletion restored dystrophin expression in the mdx mouse model and partially recovered muscle function. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Treated mice were shown to partially recover muscle functional deficiencies.5”
§ What is CRISPR/Cas9? > Correction of genetic disorders
What the sources say
- Supportedcites [5] source
The Abstract states that AAV-Dmd CRISPR treatment partially recovered muscle functional deficiencies in mdx mice, a model of DMD. It also reports improved muscle force and reduced force loss after damage compared with control-treated muscles. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
16 more claims · 12 with their cited sources checked
Create a free account to see all 32 claims and every source verdict.
- It may state two separate claims as one. 6
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CRISPR/Cas9 is a two-component system that involves a guide RNA specific to the gene of interest and an endonuclease that induces a site specific double-stranded DNA to allow for genetic modification.9”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [9]
Citations
Cites
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Schwank, G., Koo, B.-K., Sasselli, V., Dekkers, J. F., Heo, I., Demircan, T., Sasaki, N., Boymans, S., Cuppen, E., van der Ent, C. K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.11.002 · Cited by 1,424
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., et al. (2016) · Science · doi:10.1126/science.aad5143 · Cited by 1,144
CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes
Liang, P., Xu, Y., Zhang, X., Ding, C., Huang, R., Zhang, Z., Lv, J., Xie, X., Chen, Y., Li, Y., et al. (2015) · Protein & Cell · doi:10.1007/s13238-015-0153-5 · Cited by 1,135
In vivo gene editing in dystrophic mouse muscle and muscle stem cells
Tabebordbar, M., Zhu, K., Cheng, J. K. W., Chew, W. L., Widrick, J. J., Yan, W. X., Maesner, C., Wu, E. Y., Xiao, R., Ran, F. A., et al. (2016) · Science · doi:10.1126/science.aad5177 · Cited by 1,046
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P. A., Jacks, T., & Anderson, D. G. (2014) · Nature Biotechnology · doi:10.1038/nbt.2884 · Cited by 951
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., et al. (2015) · Nature · doi:10.1038/nature15521 · Cited by 886
Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA
Long, C., McAnally, J. R., Shelton, J. M., Mireault, A. A., Bassel-Duby, R., & Olson, E. N. (2014) · Science · doi:10.1126/science.1254445 · Cited by 720
Generation of knock-in primary human T cells using Cas9 ribonucleoproteins
Schumann, K., Lin, S., Boyer, E., Simeonov, D. R., Subramaniam, M., Gate, R. E., Haliburton, G. E., Ye, C. J., Bluestone, J. A., Doudna, J. A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512503112 · Cited by 702
Don’t edit the human germ line
Lanphier, E., Urnov, F., Haecker, S. E., Werner, M., & Smolenski, J. (2015) · Nature · doi:10.1038/519410a · Cited by 530
Cited by
The Impact of Plant-Parasitic Nematodes on Agriculture and Methods of Control
Bernard, G. C., Egnin, M., & Bonsi, C. (2017) · Nematology - Concepts, Diagnosis and Control · doi:10.5772/intechopen.68958 · Cited by 216
Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum
Guerrini, R., Conti, V., Mantegazza, M., Balestrini, S., Galanopoulou, A. S., & Benfenati, F. (2023) · Physiological Reviews · doi:10.1152/physrev.00063.2021 · Cited by 196
Current State and Future Directions in the Therapy of ALS
Tzeplaeff, L., Wilfling, S., Requardt, M. V., & Herdick, M. L. (2023) · Cells · doi:10.3390/cells12111523 · Cited by 187
Towards application of CRISPR-Cas12a in the design of modern viral DNA detection tools (Review)
Dronina, J., Samukaitė-Bubnienė, U., & Ramanavičius, A. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01246-7 · Cited by 151
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Metadata
- Authors
- Redman, M., King, A., Watson, C., & King, D.
- Affiliations
- University of York (GB)
- John Radcliffe Hospital (GB)
- Churchill Hospital (GB)
- Sheffield Children's Hospital (GB)
- Corresponding author
- King, David
- Venue
- Archives of disease in childhood - Education & practice edition
- Publisher
- BMJ
- Published
- 2016-04-08
- Volume
- 101
- Issue
- 4
- Pages
- 213-215
- ISSN
- 1743-0585 (ISSN-L)
- 1743-0593
- PMC
- PMC4975809
- OpenAlex
- W2339144537
- Cited by
- 248
- References
- 14
- Citations by year
- 2026: 25 · 2025: 71 · 2024: 56 · 2023: 30 · 2022: 29 · 2021: 15 · 2020: 9 · 2019: 5 · 2018: 2 · 2017: 4 · 2016: 1
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Archives of Disease in Childhood Education & Practice (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Wellcome Trust (108785/Z/15/Z)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- CRISPR/Cas9, genome editing, guide RNA, Cas9 endonuclease, clinical application, gene therapy, genetic disorders, ethical controversies, HIV treatment, cancer immunotherapy
- MeSH terms
- Adolescent, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Pediatrics, Disease Management, Gene Silencing, Young Adult, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: What is CRISPR/Cas9? https://app.cochat.ai/papers/10.1136/archdischild-2016-310459
- The paper
- Redman, M., King, A., Watson, C., & King, D. (2016). What is CRISPR/Cas9? Archives of disease in childhood - Education & practice edition. https://doi.org/10.1136/archdischild-2016-310459
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.